Aclaris Therapeutics, Inc. (ACRS)

Market Cap	1.05B
Revenue (ttm)	6.14M
Net Income (ttm)	-83.27M
Shares Out	66.67M
EPS (ttm)	-1.36
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	278,470
Open	14.80
Previous Close	14.67
Day's Range	14.76 - 16.03
52-Week Range	9.26 - 18.75
Beta	0.60
Analysts	Buy
Price Target	35.50 (+125.5%)
Earnings Date	Oct 31, 2022

About ACRS

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of ...

• Industry: Pharmaceuticals
• IPO Date: Oct 7, 2015
• CEO: Neal Walker
• Employees: 72
• Stock Exchange: NASDAQ
• Ticker Symbol: ACRS

Full Company Profile

Financial Performance

In 2021, ACRS's revenue was $6.76 million, an increase of 4.30% compared to the previous year's $6.48 million. Losses were -$90.87 million, 78.1% more than in 2020.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for ACRS stock is "Buy." The 12-month stock price forecast is 35.5, which is an increase of 125.54% from the latest price.

Price Target

$35.5

(125.54% upside)

Analyst Consensus: Buy

Stock Forecasts